Subjective cognitive complaints one year after ceasing adjuvant endocrine therapy for early-stage breast cancer: Findings from the Breast International Group (BIG) 1-98 trial.

被引：0
|
作者：
Phillips, Kelly-Anne
Ribi, Karin
Aldridge, Julie
Thompson, Alastair Mark
Harvey, Vernon J.
Thurlimann, Beat J. K.
Cardoso, Fatima
Pagani, Olivia
Coates, Alan Stuart
Goldhirsch, Aron
Price, Karen N.
Gelber, Richard D.
Bernhard, Juerg
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Int Breast Canc Study Grp, Bern, Switzerland
[3] Dana Farber Canc Inst, Int Breast Canc Study Grp, Ctr Stat, Boston, MA 02115 USA
[4] Univ Dundee, Dundee, Scotland
[5] Auckland Hosp, Auckland, New Zealand
[6] Kantonsspital St Gallen, St Gallen, Switzerland
[7] Inst Jules Bordet, B-1000 Brussels, Belgium
[8] Inst Oncol Southern Switzerland, Lugano Viganello, Switzerland
[9] Univ Sydney, Sydney, NSW 2006, Australia
[10] European Inst Oncol, Milan, Italy
[11] IBCSG Stat Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9022
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study
    E. A. Underwood
    K. J. Jerzak
    G. Lebovic
    P. A. Rochon
    C. Elser
    K. I. Pritchard
    M. C. Tierney
    Supportive Care in Cancer, 2019, 27 : 3035 - 3043
  • [22] DESIGN AND EVOLUTION OF BIG 1-98: A RANDOMIZED, DOUBLE-BLIND, PHASE-III STUDY COMPARING LETROZOLE AND TAMOXIFEN AS ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH RECEPTOR-POSITIVE, EARLY BREAST CANCER - BIG 1-98 COLLABORATIVE AND INTERNATIONAL BREAST CANCER STUDY GROUPS
    Giobbie-Hurder, A. E.
    Gelber, R. D.
    ANNALS OF ONCOLOGY, 2008, 19 : 80 - 80
  • [23] Historical early treatment effects of adjuvant endocrine therapy for breast cancer in high-risk subgroups: Reanalysis of BIG 1-98, SOFT and TEXT.
    Regan, Meredith M.
    Niman, Samuel M.
    Fleming, Gini F.
    Walley, Barbara
    Viale, Giuseppe
    Thurlimann, Beat J. K.
    Loi, Sherene
    Colleoni, Marco
    Pagani, Olivia
    Francis, Prudence A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of international breast cancer study group trial IV
    Crivellari, D
    Price, K
    Gelber, RD
    Castiglione-Gertsch, M
    Rudenstam, CM
    Lindtner, J
    Fey, MF
    Senn, HJ
    Coates, AS
    Collins, J
    Goldhirsch, A
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4517 - 4523
  • [25] Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98
    Coates, Alan S.
    Keshaviah, Aparna
    Thuerlimann, Beat
    Mouridsen, Henning
    Mauriac, Louis
    Forbes, John F.
    Paridaens, Robert
    Castiglione-Gertsch, Monica
    Gelber, Richard D.
    Colleoni, Marco
    Lang, Istvan
    Del Mastro, Lucia
    Smith, Ian
    Chirgwin, Jacquie
    Nogaret, Jean-Marie
    Pienkowski, Tadeusz
    Wardley, Andrew
    Jakobsen, Erik H.
    Price, Karen N.
    Goldhirsch, Aron
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 486 - 492
  • [26] Changes in adjuvant endocrine therapy over one year among postmenopausal women with early-stage breast cancer initiating aromatase inhibitors.
    LaMorte, Danielle Lindsay
    Hartmann, Katherine E.
    Abramson, Vandana Gupta
    Mayer, Ingrid A.
    Peacock, Nancy Walker
    Cella, David
    Castel, Liana Desharnais
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (34)
  • [27] Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer
    Giobbie-Hurder, Anita
    Price, Karen N.
    Gelber, Richard D.
    CLINICAL TRIALS, 2009, 6 (03) : 272 - 287
  • [28] PREDICTORS OF HYPERTENSION IN IBCSG 18-98/BIG 1-98: ADJUVANT THERAPY FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, EARLY BREAST CANCER
    Rabaglio-Poretti, M.
    Giobbie-Hurder, A.
    Thuerlimann, B.
    Regan, M.
    Ejlertsen, B.
    Debled, M.
    Colleoni, M.
    Goldhirsch, A.
    Coates, A.
    Gelber, R. D.
    ANNALS OF ONCOLOGY, 2014, 25
  • [29] CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
    Regan, Meredith M.
    Leyland-Jones, Brian
    Bouzyk, Mark
    Pagani, Olivia
    Tang, Weining
    Kammler, Roswitha
    Dell'Orto, Patrizia
    Biasi, Maria Olivia
    Thuerlimann, Beat
    Lyng, Maria B.
    Ditzel, Henrik J.
    Neven, Patrick
    Debled, Marc
    Maibach, Rudolf
    Price, Karen N.
    Gelber, Richard D.
    Coates, Alan S.
    Goldhirsch, Aron
    Rae, James M.
    Viale, Giuseppe
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06): : 441 - 451
  • [30] 12 years' median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer
    Thuerlimann, B.
    Giobbie-Hurder, A.
    Colleoni, M.
    Jensen, M-B
    Ejlertsen, B.
    de Azambuja, E.
    Neven, P.
    Lang, I.
    Gladieff, L.
    Bonnefoi, H.
    Harvey, V. J.
    Spazzapan, S.
    Tondini, C.
    Price, K.
    Piccart-Gebhart, M.
    Regan, M. M.
    Gelber, R. D.
    Coates, A. S.
    Goldhirsch, A.
    CANCER RESEARCH, 2017, 77
12345